Engineering any genome, at any site, in any way
At the forefront of a revolutionary field offering profound benefits to human health and society
Focused on the advancement of new applications for CRISPR-based technologies
Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech
Caribou Biosciences' Co-Founder Dr. Jennifer Doudna and Chairman of the Board Rodolphe Barrangou Selected for 2016 Canada Gairdner AwardsMarch 24, 2016
Caribou Biosciences and Integrated DNA Technologies (IDT) Announce Non-Exclusive License Agreement for CRISPR-Cas9 ReagentsFebruary 23, 2016
Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing. Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole.
Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.